Impact of liver cirrhosis on the clinical outcomes of patients with COVID-19: a nationwide cohort study of Korea
Authors:
Open Access
- 1 September 2021
- journal article
- research article
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 36 (5) , 1092-1101
Abstract
Background/Aims: The impact of liver cirrhosis (LC) on the clinical outcomes of patients with coronavirus disease 2019 (COVID-19) remains elusive. This study evaluated the association between LC and the development of severe complications from COVID-19.Methods: We used the National Health Insurance claims data of Korea. We included 234,427 patients older than 19 years who tested for severe acute respiratory syndrome coronavirus 2. Patients with LC who were infected with COVID-19 (n = 67, LC+ COVID+) were matched with those with cirrhosis only (n = 332, LC+ COVID–) and those with COVID-19 only (n = 333, LC– COVID+) using a propensity score in a 1:5 ratio. The primary outcome was the development of severe complications.Results: Of the matched patients, the mean age was 60 years and 59.7% were male. Severe complications occurred in 18, 54, and 60 patients in the LC+ COVID+, LC+ COVID–, and LC– COVID+ groups, respectively. After adjusting for comorbidities, there was no significant difference in the risk of developing severe complications from COVID-19 between the LC+ COVID+ and LC– COVID+ groups but significant difference exists between the LC+ COVID+ and LC+ COVID–. Older age, hypertension, cancer, chronic obstructive pulmonary disease, and a higher Charlson comorbidity index were associated with a higher risk of severe complications in patients with cirrhosis and COVID-19.Conclusions: Our study suggests that LC was not independently associated with the development of severe complications, including mortality, in patients with COVID-19. Our results need to be evaluated through a large, prospective study.Keywords
This publication has 35 references indexed in Scilit:
- Clinical Characteristics of Coronavirus Disease 2019 in ChinaNew England Journal of Medicine, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- 2019 Novel Coronavirus—Important Information for CliniciansJAMA, 2020
- Liver cirrhosis and cancer: comparison of mortalityHepatology International, 2018
- Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus‐endemic populationHepatology, 2017
- Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trialThe Lancet, 2016
- Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevanceJournal of Hepatology, 2014
- Low Incidence of Severe Liver Events in HIV Patients With and Without Hepatitis C or B Coinfection Receiving Lopinavir/RitonavirHIV Research & Clinical Practice, 2006
- How to measure comorbidity: a critical review of available methodsJournal of Clinical Epidemiology, 2004
- How to measure comorbiditya critical review of available methodsJournal of Clinical Epidemiology, 2003